cardiovascular disease

Insurance Tara Bannow

STAT Plus: MassMutual is rolling out free genetic testing for members, a dicey area for life insurers

Health tech Lizzy Lawrence and Matthew Herper

STAT Plus: Device made by company J&J is buying for $13 billion clears hurdle in independent study

Health tech Lizzy Lawrence

STAT Plus: In first big randomized trial, Abiomed’s heart pump reduced deaths in heart attack patients

Health Elaine Chen

Large trial challenges common practice of prescribing beta blockers after heart attack

Biotech Elaine Chen

STAT Plus: Alnylam’s twice-a-year drug lowered blood pressure when combined with common pills

Pharma Elaine Chen

STAT Plus: Positive trial results set up obesity drug Wegovy for use against heart failure

Health tech Lizzy Lawrence

STAT Plus: Johnson & Johnson to buy Shockwave Medical for $13.1 billion

Health tech Lizzy Lawrence

STAT Plus: FDA approves TriClip for tricuspid heart valve disease, pitting Abbott against Edwards

Health tech Lizzy Lawrence

STAT Plus: FDA clears digital stethoscope company’s AI algorithm for heart failure

Pharma Elaine Chen

STAT Plus: Merck drug for rare cardiovascular condition approved in U.S.

Health Deborah Balthazar

Disparities in donor acceptance rates point to need for more equitable heart transplant care

Health Elaine Chen

STAT Plus: Despite new Wegovy coverage, Medicare patients may face high drug costs and other hurdles

Pharma Elaine Chen

STAT Plus: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label

In the Lab Elaine Chen

Microplastics found in blood vessels linked to greater risk of heart problems, study finds

Letters to the editor Torie Bosch

What STAT readers think about octogenarian presidents

Health Annalisa Merelli

Niacin has long been a public health darling. But an excess could be bad for the heart, study suggests

Health tech Mario Aguilar

STAT Plus: Digital tools helped lower blood pressure in marginalized patient groups

First Opinion Arthur L. Kellermann

The health care system is ignoring world’s most promising approach to preventing cardiovascular disease

Health tech Lizzy Lawrence

STAT Plus: FDA advisory panel votes in favor of Abbott’s new heart device

Health Elaine Chen

Stem cell study offers clue to South Asians’ increased risk of cardiovascular disease

Business Tara Bannow

STAT Plus: Lasers, cardiology, clinical trials: 2023’s top private equity targets

Biotech Damian Garde

STAT Plus: At JPM, Verve details plot to take genome editing mainstream

Health Gina Ryder

Cardiac psychologists are pushing to protect heart patients’ often-overlooked mental health

Health Elaine Chen

STAT Plus: Wegovy may have another helpful trick: fighting inflammation via the brain, study finds

Health Elaine Chen

People with congenital heart disease are living longer — but facing new threat of heart failure

Health tech Lizzy Lawrence

STAT Plus: FDA approves Medtronic high blood pressure device despite a negative advisory panel vote

Biotech Matthew Herper

STAT Plus: Eli Lilly’s chief scientist on new obesity drug data, gene editing, and a potential new heart drug

Pharma Elaine Chen

STAT Plus: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation

Biotech Elaine Chen

STAT Plus: Anthos stroke drug appears safer than common blood thinner in mid-stage trial